Sun Pharmaceutical Industries Ltd Opens Strong with Significant Gap Up on 3 Feb 2026

Opening Price Surge and Intraday Movement

The stock opened sharply higher at Rs 1710, marking a 5.41% gain over the prior session’s close. This gap up was a notable development given the stock’s recent performance, which has seen a steady upward trajectory over the past four trading days, accumulating a total return of 6.41%. The intraday high reached Rs 1725, representing a 5.9% increase from the previous close, before settling with a day change of 3.65% by market close.

This price action indicates that the initial enthusiasm was somewhat tempered as the session progressed, yet the stock maintained a solid gain, closing well above its 5-day and 20-day moving averages. However, it remained below the longer-term 50-day, 100-day, and 200-day moving averages, suggesting that while short-term momentum is positive, the stock has yet to break through some key resistance levels on a longer timeframe.

Sector and Market Context

The Pharmaceuticals & Biotechnology sector, in which Sun Pharmaceutical operates, gained 2.81% on the day, indicating a broadly favourable environment for stocks in this space. Sun Pharma outperformed the sector by 1.01%, reflecting stronger relative strength. Comparatively, the Sensex index rose by 2.51%, with Sun Pharma’s 3.65% gain exceeding the benchmark’s performance, underscoring the stock’s leadership within its industry group on this trading day.

Despite the positive short-term momentum, the stock’s one-month performance remains slightly negative at -2.42%, closely mirroring the Sensex’s -2.39% over the same period. This suggests that while recent trading sessions have been encouraging, the stock is still navigating broader market pressures that have affected its medium-term trend.

Technical Indicators and Momentum Analysis

Technical analysis presents a mixed picture for Sun Pharmaceutical Industries Ltd. On a daily basis, moving averages signal a mildly bullish trend, supported by the stock trading above its 5-day and 20-day averages. However, weekly and monthly indicators such as MACD and KST remain mildly bearish, indicating some caution in the medium term.

The Relative Strength Index (RSI) on both weekly and monthly charts shows no definitive signal, suggesting the stock is neither overbought nor oversold at these intervals. Bollinger Bands indicate a mildly bearish stance on the weekly chart and sideways movement monthly, reflecting consolidation phases rather than strong directional moves.

Volume-based indicators such as On-Balance Volume (OBV) show no clear trend on weekly or monthly timeframes, implying that volume has not decisively confirmed price movements. Dow Theory assessments also indicate no clear trend on weekly or monthly scales, reinforcing the notion of a market in transition rather than a decisive directional breakout.

Gap Up Implications and Price Action Considerations

The significant gap up opening at 5.41% suggests that overnight developments or market sentiment shifts have positively influenced the stock’s valuation. While the exact catalyst is not specified, the price jump indicates strong demand at the open, which was sustained through the day with the stock closing well above its short-term moving averages.

Such a gap up often raises the question of whether the stock will maintain its elevated levels or experience a gap fill, where prices retrace to the previous close. In this case, the sustained intraday momentum and outperformance relative to sector and benchmark indices suggest that the gap fill risk is limited in the immediate term. However, the presence of resistance at longer-term moving averages may cap upside potential until these levels are decisively breached.

Mojo Score and Rating Update

Sun Pharmaceutical Industries Ltd currently holds a Mojo Score of 62.0, categorised as a Hold rating. This represents a downgrade from its previous Buy rating, which was revised on 19 Jan 2026. The downgrade reflects a reassessment of the stock’s medium-term outlook, balancing recent gains against technical and fundamental factors.

The company’s market capitalisation grade remains at 1, indicating its status as a large-cap entity within the Pharmaceuticals & Biotechnology sector. This classification underscores the stock’s significance in the market and its role as a bellwether for the industry.

Summary of Price and Performance Metrics

To summarise, Sun Pharmaceutical Industries Ltd’s price action on 3 Feb 2026 was characterised by a strong gap up opening of 5.41%, an intraday high of Rs 1725 (5.9% gain), and a closing day change of 3.65%. The stock outperformed its sector by 1.01% and the Sensex by 1.14%, continuing a four-day streak of gains that have cumulatively returned 6.41%.

While short-term technical indicators are mildly bullish, medium-term signals remain cautious, with key moving averages above the current price level. The stock’s Mojo rating adjustment to Hold reflects this nuanced outlook, balancing recent positive momentum against broader market and technical considerations.

Conclusion

Sun Pharmaceutical Industries Ltd’s significant gap up opening and sustained intraday gains on 3 Feb 2026 highlight a positive market response within the Pharmaceuticals & Biotechnology sector. The stock’s outperformance relative to sector peers and the Sensex indicates strong short-term momentum, supported by technical signals on daily charts. However, medium-term indicators and the recent rating downgrade suggest that investors should monitor key resistance levels and broader market trends for further directional clarity.

Unlock special upgrade rates for a limited period. Start Saving Now →